EpigralNSE:EPIGRAL -3.42%80 Days Payable is 55.76 as of Mar. 2026, which is 16% above its 10-year median of 48.13. GuruFocus rates NSE:EPIGRAL with a GF Score™ of 80/100 and a GF Value™ of ₹1,775.83 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,551 Chemicals companies, Epigral ranks worse than 58.28% on this metric.
Epigral's average Accounts Payable for the
three
months ended in Mar. 2026 was ₹2,597 Mil. Epigral's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹4,250 Mil.
Hence, Epigral's Days Payable for the
three
months ended in Mar. 2026 was 55.76.
The historical rank and industry rank for Epigral's Days Payable or its related term are showing as below:
NSE:EPIGRAL'
s Days Payable Range Over the Past 10 Years
Min: 30.99 Med: 48.13 Max: 54.31
Current: 51.98
During the past 9 years, Epigral's highest Days Payable was 54.31. The lowest was 30.99. And the median was 48.13.
NSE:EPIGRAL's Days Payable is ranked worse than 58.28% of 1551
companies
in the Chemicals industry
Industry Median: 59.87
vs NSE:EPIGRAL: 51.98
Epigral's Days Payable
increased
from Mar. 2025 (51.51) to Mar. 2026 (55.76).
It may suggest that Epigraldelayed paying its suppliers.
Epigral Days Payable Related Terms
Epigral Days Payable Historical Data
* Premium members only.
The historical data trend for Epigral's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Epigral's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigral Days Payable vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Epigral's Days Payable distribution charts can be found below:
* The bar in red indicates where Epigral's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Epigral's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigral (NSE:EPIGRAL) has a Days Payable of 55.76 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Epigral and its competitors. This is 16% above median its historical median of 48.13. Over the past decade, Epigral's Days Payable has ranged from 30.99 to 54.31. According to the industry distribution chart, Epigral ranks #904 out of 1551 companies in the Chemicals industry, placing it in the top 58.3%.
Is Epigral's Days Payable too high?
Epigral's current Days Payable of 55.76 is 16% above median its 10-year median of 48.13. Over the past 10 years, this metric has ranged from a low of 30.99 to a high of 54.31. The Chemicals industry median Days Payable is 59.87. Epigral's value of 55.76 is 6.9% below this industry median. Based on the distribution chart, Epigral ranks #904 out of 1551 companies in the Chemicals industry, which is below the industry midpoint. Overall, Epigral has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Epigral's Days Payable compare to DOW?
According to the Chemicals industry distribution chart, Epigral ranks #904 out of 1551 companies for Days Payable. This places Epigral in the lower half of its industry. The industry median Days Payable is 59.87. Epigral's value of 55.76 is 6.9% below this benchmark. Historically, Epigral's own Days Payable has ranged from 30.99 to 54.31 over the past decade. While the company's 10-year median is 48.13 vs. the industry median of 59.87, Epigral has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Chemicals company?
The median Days Payable among Chemicals companies is 59.87, based on 1,551 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epigral's current Days Payable of 55.76 is 6.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Epigral and its competitors. For the Chemicals industry, the median Days Payable is 59.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigral's current Days Payable is 55.76, which is 16% above median its own 10-year median of 48.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigral stock overvalued right now?
Based on GuruFocus' analysis, Epigral (NSE:EPIGRAL) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹1,775.83, compared to a current price of ₹987.70 — trading 44.4% below its estimated fair value. The current Days Payable is 55.76, which is 16% above median its 10-year median of 48.13 and 6.9% below the Chemicals industry median of 59.87. Epigral's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Epigral (NSE:EPIGRAL), the current Days Payable is 55.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigral (NSE:EPIGRAL) Overvalued in 2026?
Based on GuruFocus' analysis, Epigral stock appears to be undervalued.
The current stock price of ₹987.70 is trading 44.4% below its estimated GF Value™ of ₹1,775.83.
GuruFocus considers Epigral to be Significantly Undervalued.
Key valuation signals for NSE:EPIGRAL:
Days Payable: 55.76 (16% above median its 10-year median of 48.13)
GF Value™: ₹1,775.83 vs. price of ₹987.70 (44.4% below fair value)
Industry Position: 6.9% below the Chemicals median (#904 of 1551)
No single metric tells the full story. See the NSE:EPIGRAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigral Ltd is a producer of Chlor-Alkali and its Derivatives and specialty chemicals with backward and forward integration facilities. It manufactures Caustic Soda, Caustic Potash, CPVC Resin, Epichlorohydrin, Chlorine, Hydrogen, Chloromethanes, and Hydrogen Peroxide. The company is focused on servicing domestic as well as international markets.
80GF Score
Get the complete analysis for NSE:EPIGRAL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EPIGRAL has been successfully added to your 
